NDAINTRAVENOUSSOLUTION
Approved
Feb 2020
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
4/8 — Partial
ANJESO (meloxicam) by Ascentage Pharma is analgesic, anti-inflammatory, and antipyretic properties. First approved in 2020.
Drug data last refreshed 4h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ANJESO is an intravenous formulation of meloxicam, a nonsteroidal anti-inflammatory drug (NSAID) that provides analgesic, anti-inflammatory, and antipyretic effects through inhibition of cyclooxygenase (COX-1 and COX-2) enzymes. It reduces prostaglandin synthesis in peripheral tissues, thereby decreasing pain signaling and inflammation. The IV route enables rapid onset of action for acute pain management in hospital and surgical settings.
Peak12.7 years to LOE
Product is in peak commercial phase with established market presence; brand team likely at stable headcount focused on market maintenance and physician engagement.
Mechanism of Action
analgesic, anti-inflammatory, and antipyretic properties. The mechanism of action of meloxicam, like that of other NSAIDs, is not completely understood but involves inhibition of cyclooxygenase (COX-1 and COX-2). Meloxicam is a potent inhibitor of prostaglandin synthesis in vitro. Meloxicam…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Oral Levonorgestrel Plus Meloxicam, IG-002 Delays Ovulation in Normal Menstruating Women by Seven Days
Started Jun 2022
21 enrolled
Pregnancy Prevention
A Study to Compare the Amount of Meloxicam in the Blood When it is Taken as Capsules or as Tablets
Started Oct 2018
26 enrolled
Healthy
This Study is Randomised, Single Oral Dose Bioequivalence Study of Meloxicam GSK 15 MG Tablets.
Started Sep 2013
28 enrolled
Arthritis, Rheumatoid
Effect Of Meloxicam Versus Placebo In Mainland Chinese Patients With Osteoarthritis Of The Knee
Started Oct 2011
408 enrolled
Osteoarthritis of the Knee
Bioequivalence Study of Meloxicam Capsules 15 mg (Mobic® Capsules 15 mg) Versus Meloxicam Tablets 15 mg (Mobic® Tablets 15 mg) in Healthy Adult Volunteers
Started Nov 2008
6 enrolled
Healthy
Worked on ANJESO at Ascentage Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.